C4 Therapeutics Inc
NASDAQ:CCCC 4:00:00 PM EDT
| Market Cap (Intraday) | 110.77M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $1.52 |
| 50-Day MA | $1.47 |
| 200-Day MA | $3.48 |
C4 Therapeutics Inc Stock, NASDAQ:CCCC
490 Arsenal Way, Suite 120, Watertown, Massachusetts 02472
United States of America
Phone: +1.617.231.0700
Number of Employees: 110
Description
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.